Science Corporation Implants Vision-Restoring Chip in First Stargardt Disease Patient

Breakthrough Implant for Incurable Eye Disease

Science Corporation has successfully implanted its PRIMA vision-restoring chip into its first patient with Stargardt disease, a hereditary condition that destroys central vision and currently has no cure. The procedure took place in May at Sydney Eye Hospital in Australia as part of an ongoing clinical trial. During initial rehabilitation sessions, the patient progressed from seeing individual letters to reading complete words—a significant milestone for a technology addressing a condition affecting approximately 150,000 people worldwide.

Max Hodak, the company's CEO and former president and co-founder of Neuralink, presented the development at TechCrunch Disrupt 2026. Hodak framed retinal prostheses like PRIMA as brain-computer interfaces (BCIs), positioning them alongside cochlear implants and motor prostheses as diverse applications of neural engineering rather than only brain-control devices.

How the Device Works and Current Limitations

The PRIMA implant is a two-millimeter square chip surgically placed in the back of the eye where photoreceptors have deteriorated. Patients wear camera-equipped glasses that capture visual information and transmit it wirelessly to the implant, which functions as artificial photoreceptors. The current version provides sharp, high-contrast black-and-white vision but has significant constraints: a narrow field of view comparable to looking through a straw, monochrome imaging, and the ability to discern only a couple of letters at a time.

Hodak acknowledged these limitations are engineering challenges with clear solutions. The company is developing a next-generation implant expected to reach human trials within the next year, with plans to achieve native-level visual acuity within five years. The roadmap involves expanding the implant's physical size to increase field of view while simultaneously miniaturizing electrodes to match biological precision more closely.

Broader BCI Strategy and Future Applications

Science Corporation, founded in 2021 after Hodak departed Neuralink, originally intended to focus on brain-computer interface technology but chose to establish clinical credibility and business sustainability through vision restoration first. The company's approach differs from Neuralink's methodology: its BCI sensor will sit on top of the brain inside the skull rather than penetrating brain tissue directly.

Beyond ophthalmology, Hodak outlined ambitious applications for the company's neural engineering platform. The company plans to address a neurodegenerative disease in the near term that Hodak described as widely recognized but did not name publicly. Longer-term targets include stroke rehabilitation, where implants could theoretically bridge damaged neural connections between brain regions and potentially add new functional cortical areas—capabilities unavailable with conventional electrode technology. Hodak expressed the company's ultimate mission as understanding how the brain generates consciousness and developing engineered brain systems.

Vision for Mass Adoption

Hodak suggested that brain-computer interface technology will eventually become commonplace, particularly for aging populations. While Science Corporation is not designing for healthy middle-aged adults, Hodak predicted many people will require some form of BCI by their 60s or 70s. He emphasized the company's focus on extending not just lifespan but healthspan—the period of life lived in good health.

PRIMA already has regulatory approval in Europe for patients with geographic atrophy, an advanced form of age-related macular degeneration. The successful implantation in a Stargardt disease patient demonstrates the technology's potential application across multiple retinal conditions. This expansion validates Science Corporation's strategy of using vision restoration as the initial clinical foothold before advancing toward more complex neurological applications.